Various clinical studies have indicated only probably less than 25% of metastatic breast tumors harbor ERα mutations that may drive resistance (46, 47), suggesting perturbations in growth factor or other molecular signaling pathways as major component mediating endocrine independence. This evidence concerns the gene ESR1 and breast neoplasm.